JP2021087433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021087433A5 JP2021087433A5 JP2021016537A JP2021016537A JP2021087433A5 JP 2021087433 A5 JP2021087433 A5 JP 2021087433A5 JP 2021016537 A JP2021016537 A JP 2021016537A JP 2021016537 A JP2021016537 A JP 2021016537A JP 2021087433 A5 JP2021087433 A5 JP 2021087433A5
- Authority
- JP
- Japan
- Prior art keywords
- acid sequence
- pharmaceutical composition
- nucleic acid
- composition according
- recombinant nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 56
- 150000007523 nucleic acids Chemical group 0.000 claims 55
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 51
- 229920001184 polypeptide Polymers 0.000 claims 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 10
- 241000701022 Cytomegalovirus Species 0.000 claims 6
- 108091005804 Peptidases Proteins 0.000 claims 6
- 239000004365 Protease Substances 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 6
- 241000700605 Viruses Species 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 238000003776 cleavage reaction Methods 0.000 claims 4
- 239000013612 plasmid Substances 0.000 claims 4
- 230000007017 scission Effects 0.000 claims 4
- 241001502567 Chikungunya virus Species 0.000 claims 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 244000052769 pathogen Species 0.000 claims 3
- 241000725619 Dengue virus Species 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023040876A JP2023080085A (ja) | 2012-12-13 | 2023-03-15 | Ｄｎａ抗体構築物およびその使用方法 |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261737094P | 2012-12-13 | 2012-12-13 | |
| US61/737,094 | 2012-12-13 | ||
| US201361881376P | 2013-09-23 | 2013-09-23 | |
| US61/881,376 | 2013-09-23 | ||
| US201361896646P | 2013-10-28 | 2013-10-28 | |
| US61/896,646 | 2013-10-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548014A Division JP6898060B2 (ja) | 2012-12-13 | 2013-12-13 | Ｄｎａ抗体構築物およびその使用方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023040876A Division JP2023080085A (ja) | 2012-12-13 | 2023-03-15 | Ｄｎａ抗体構築物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021087433A JP2021087433A (ja) | 2021-06-10 |
| JP2021087433A5 true JP2021087433A5 (enExample) | 2021-07-26 |
Family
ID=50935092
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548014A Active JP6898060B2 (ja) | 2012-12-13 | 2013-12-13 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2019061531A Pending JP2019115355A (ja) | 2012-12-13 | 2019-03-27 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2020035240A Pending JP2020108381A (ja) | 2012-12-13 | 2020-03-02 | Ｄｎａ抗体構築物及びその使用方法 |
| JP2021016537A Withdrawn JP2021087433A (ja) | 2012-12-13 | 2021-02-04 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2023040876A Pending JP2023080085A (ja) | 2012-12-13 | 2023-03-15 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2023108341A Pending JP2023138998A (ja) | 2012-12-13 | 2023-06-30 | Ｄｎａ抗体構築物及びその使用方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015548014A Active JP6898060B2 (ja) | 2012-12-13 | 2013-12-13 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2019061531A Pending JP2019115355A (ja) | 2012-12-13 | 2019-03-27 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2020035240A Pending JP2020108381A (ja) | 2012-12-13 | 2020-03-02 | Ｄｎａ抗体構築物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023040876A Pending JP2023080085A (ja) | 2012-12-13 | 2023-03-15 | Ｄｎａ抗体構築物およびその使用方法 |
| JP2023108341A Pending JP2023138998A (ja) | 2012-12-13 | 2023-06-30 | Ｄｎａ抗体構築物及びその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9994629B2 (enExample) |
| EP (1) | EP2931318A4 (enExample) |
| JP (6) | JP6898060B2 (enExample) |
| KR (4) | KR20150093834A (enExample) |
| CN (1) | CN104853782A (enExample) |
| AU (7) | AU2013358944B2 (enExample) |
| BR (2) | BR112015013700A8 (enExample) |
| CA (1) | CA2889723A1 (enExample) |
| EA (1) | EA201591131A1 (enExample) |
| HK (1) | HK1213481A1 (enExample) |
| MX (4) | MX2015007575A (enExample) |
| MY (1) | MY175708A (enExample) |
| SG (1) | SG10202002718RA (enExample) |
| WO (1) | WO2014093894A2 (enExample) |
| ZA (1) | ZA201503583B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1213481A1 (zh) * | 2012-12-13 | 2016-07-08 | The Trustees Of The University Of Pennsylvania | Dna抗体构建体及其使用方法 |
| CN105829341A (zh) * | 2013-12-13 | 2016-08-03 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
| US10166288B2 (en) * | 2014-10-01 | 2019-01-01 | The Trustees Of The University Of Pennsylvania | Vaccines having an antigen and interleukin-21 as an adjuvant |
| CN107427566B (zh) * | 2014-12-01 | 2021-08-17 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
| PE20181167A1 (es) | 2015-10-25 | 2018-07-19 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih |
| WO2017106326A1 (en) * | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
| AU2017238168B2 (en) * | 2016-03-21 | 2024-06-13 | Sarah Elliott | DNA antibody constructs and method of using same |
| HUE063824T2 (hu) | 2016-04-13 | 2024-02-28 | Sanofi Sa | Trispecifikus és/vagy trivalens kötõfehérjék |
| CN110072554A (zh) * | 2016-05-05 | 2019-07-30 | 宾夕法尼亚大学理事会 | 用于抗铜绿假单胞菌的dna抗体构建体 |
| KR20190031439A (ko) * | 2016-05-05 | 2019-03-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Il-6 및 cd126을 표적으로 하는 dna 단클론성 항체 |
| CN120350015A (zh) * | 2016-05-05 | 2025-07-22 | 宾夕法尼亚大学理事会 | 靶向检查点分子的dna单克隆抗体 |
| KR20240155978A (ko) * | 2016-05-05 | 2024-10-29 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 인플루엔자 바이러스를 표적으로 하는 dna 단일 클론 항체 |
| EP3515482A4 (en) | 2016-09-19 | 2020-09-30 | The Wistar Institute Of Anatomy And Biology | ASSOCIATION OF NEW ZIKA VIRUS VACCINES AND ANTI-DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST ZIKA VIRUS |
| TW202300515A (zh) | 2016-10-20 | 2023-01-01 | 法商賽諾菲公司 | 抗ｃｈｉｋｖ抗體及其用途 |
| KR20190116975A (ko) * | 2016-11-07 | 2019-10-15 | 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 | 라임병에 사용하기 위한 dna 항체 작제물 |
| EP3606552A4 (en) | 2017-04-07 | 2020-08-05 | The Rockefeller University | COMPOSITIONS AND METHODS RELATING TO HUMAN NEUTRALIZING ANTIBODIES DIRECTED AGAINST ZIKA VIRUS AND DENGUE VIRUS 1 |
| TWI673285B (zh) * | 2017-05-22 | 2019-10-01 | 國立成功大學 | 抗－登革熱病毒抗體、包含該抗體之藥學組合物及其用途 |
| WO2019067671A1 (en) * | 2017-09-27 | 2019-04-04 | David Weiner | DNA ANTIBODY CONSTRUCTS FOR USE IN CORONAVIRUS RESPIRATORY SYNDROME OF THE MIDDLE EAST |
| WO2019152602A1 (en) * | 2018-01-31 | 2019-08-08 | The Wistar Institute Of Anatomy And Biology | Structurally modified flavivirus dmabs |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| AU2020323601A1 (en) * | 2019-07-31 | 2022-03-03 | The Wistar Institute Of Anatomy And Biology | Multivalent DNA antibody constructs and use thereof |
| JP2022549138A (ja) | 2019-09-18 | 2022-11-24 | インターガラクティック セラピューティクス インコーポレイテッド | 合成ｄｎａベクターおよびその使用法 |
| SE544001C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Novel combination of tis sequences, signal peptide sequences and nucleic acid sequences encoding heavy and light chains of an antibody |
| SE544000C2 (en) * | 2020-03-17 | 2021-10-26 | Xbrane Biopharma Ab | Novel combination of tis sequence, signal peptide sequence and nucleic acid sequence encoding a recombinant protein |
| US20230136960A1 (en) * | 2020-03-19 | 2023-05-04 | Nature's Toolbox, Inc. | Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same |
| PE20230349A1 (es) | 2020-05-14 | 2023-03-02 | Inovio Pharmaceuticals Inc | Vacunas para la papilomatosis respiratoria recurrente y metodos para usar estas |
| IL303262A (en) * | 2020-12-02 | 2023-07-01 | Univ Jefferson | Desmoglein 2-directed chimeric antigen receptor (car) constructs and methods of use |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI46572C (fi) * | 1972-04-07 | 1973-04-10 | Stroemberg Oy Ab | Jännitemuuntaja. |
| US7276488B2 (en) | 1997-06-04 | 2007-10-02 | Oxford Biomedica (Uk) Limited | Vector system |
| US20030039635A1 (en) | 1998-09-30 | 2003-02-27 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| CN1334343A (zh) * | 2000-07-14 | 2002-02-06 | 中国医学科学院肿瘤医院肿瘤研究所 | 抑制肿瘤生长的新抗体、其衍生物及其应用 |
| US20070037165A1 (en) | 2000-09-08 | 2007-02-15 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| WO2004013278A2 (en) * | 2002-08-02 | 2004-02-12 | Yuhan Corporation | Expression vectors |
| US7709224B2 (en) * | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| CN1480215A (zh) | 2003-07-07 | 2004-03-10 | 叶新新 | Sars病毒抗原抗体复合疫苗及实验动物模型与方法 |
| JP4651663B2 (ja) | 2004-05-28 | 2011-03-16 | アジェンシス，インコーポレイテッド | Ｐｓｃａタンパク質に結合する抗体および関連分子 |
| BRPI0520902B1 (pt) * | 2004-05-28 | 2021-11-30 | Agensys, Inc | Anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo que se liga a proteínas psca para diagnóstico de câncer, método para produção dos mesmos, hibridoma, polinucleotídeo, vetor, composição, ensaio para detectar a presença de uma proteína psca e método de detecção de uma proteína psca |
| WO2006017325A2 (en) | 2004-07-13 | 2006-02-16 | Cell Genesys, Inc. | Aav vector compositions and methods for enhanced expression of immunoglobulins the same |
| AU2005287404B2 (en) * | 2004-07-22 | 2009-05-07 | Genentech, Inc. | HER2 antibody composition |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006089231A2 (en) | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| US20060216722A1 (en) | 2005-03-25 | 2006-09-28 | Christer Betsholtz | Glomerular expression profiling |
| US20070065912A1 (en) | 2005-07-21 | 2007-03-22 | Abbott Laboratories | Multiple Gene Expression including sORF Constructs and Methods with Polyproteins, Pro-Proteins, and Proteolysis |
| EP2185188B1 (en) | 2007-08-22 | 2014-08-06 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions |
| CA2598966A1 (en) | 2007-09-07 | 2009-03-07 | Institut Pasteur | Anti-chikungunya monoclonal antibodies and uses thereof |
| JP2009171880A (ja) | 2008-01-23 | 2009-08-06 | Yokohama City Univ | アルツハイマー病における次世代遺伝子治療法・免疫治療法の開発 |
| MX2010009894A (es) | 2008-03-14 | 2011-02-22 | Transgene Sa | Anticuerpo contra csf-1r. |
| WO2009124312A2 (en) | 2008-04-04 | 2009-10-08 | The Trustees Of The University Of Pennsylvania | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
| WO2010043977A2 (en) | 2008-10-13 | 2010-04-22 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| WO2011003780A1 (en) * | 2009-07-06 | 2011-01-13 | F. Hoffmann-La Roche Ag | Bi-specific digoxigenin binding antibodies |
| WO2011007363A1 (en) | 2009-07-13 | 2011-01-20 | Bharat Biotech International Limited | A composition useful as rotavirus vaccine and a method therefor. |
| US20110045534A1 (en) | 2009-08-20 | 2011-02-24 | Cell Signaling Technology, Inc. | Nucleic Acid Cassette For Producing Recombinant Antibodies |
| CA2774636C (en) * | 2009-09-25 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| US8580714B2 (en) * | 2009-10-14 | 2013-11-12 | Janssen Biotech, Inc. | Methods of affinity maturing antibodies |
| US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
| CA3062786C (en) | 2010-07-09 | 2022-04-19 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
| BR112013000603A2 (pt) * | 2010-07-09 | 2016-07-05 | Jv Bio Srl | anticorpos conjugados com lipídios |
| US8637035B2 (en) | 2010-07-16 | 2014-01-28 | Academia Sinica | Anti-dengue virus antibodies |
| KR101939150B1 (ko) | 2010-11-12 | 2019-01-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 공통 전립선 항원, 이것을 암호화하는 핵산 분자, 그리고 이것을 포함하는 백신 및 용도 |
| WO2012106377A2 (en) * | 2011-01-31 | 2012-08-09 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof |
| WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| JP6091435B2 (ja) * | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| CN102199218A (zh) * | 2011-04-29 | 2011-09-28 | 中国人民解放军军事医学科学院基础医学研究所 | 一种抗Her2抗体-白细胞介素2融合蛋白及其用途 |
| US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| HK1213481A1 (zh) * | 2012-12-13 | 2016-07-08 | The Trustees Of The University Of Pennsylvania | Dna抗体构建体及其使用方法 |
| JP7078350B2 (ja) * | 2013-10-28 | 2022-05-31 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Ｄｎａ抗体構築物及びその使用方法 |
| KR102877281B1 (ko) | 2012-12-13 | 2025-10-28 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Ｗｔ１ 백신 |
| WO2014100490A1 (en) | 2012-12-19 | 2014-06-26 | Adimab, Llc | Multivalent antibody analogs, and methods of their preparation and use |
| CN105829341A (zh) | 2013-12-13 | 2016-08-03 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
-
2013
- 2013-12-13 HK HK16101459.4A patent/HK1213481A1/zh unknown
- 2013-12-13 CA CA2889723A patent/CA2889723A1/en active Pending
- 2013-12-13 WO PCT/US2013/075137 patent/WO2014093894A2/en not_active Ceased
- 2013-12-13 KR KR1020157018712A patent/KR20150093834A/ko not_active Ceased
- 2013-12-13 JP JP2015548014A patent/JP6898060B2/ja active Active
- 2013-12-13 BR BR112015013700A patent/BR112015013700A8/pt not_active Application Discontinuation
- 2013-12-13 KR KR1020237036307A patent/KR20230156146A/ko not_active Ceased
- 2013-12-13 CN CN201380065674.3A patent/CN104853782A/zh active Pending
- 2013-12-13 AU AU2013358944A patent/AU2013358944B2/en active Active
- 2013-12-13 EA EA201591131A patent/EA201591131A1/ru unknown
- 2013-12-13 MX MX2015007575A patent/MX2015007575A/es unknown
- 2013-12-13 KR KR1020217020972A patent/KR20210088741A/ko not_active Ceased
- 2013-12-13 EP EP13863143.7A patent/EP2931318A4/en active Pending
- 2013-12-13 US US14/651,740 patent/US9994629B2/en active Active
-
2014
- 2014-12-13 AU AU2014361811A patent/AU2014361811B2/en active Active
- 2014-12-13 MX MX2016007722A patent/MX388911B/es unknown
- 2014-12-13 SG SG10202002718RA patent/SG10202002718RA/en unknown
- 2014-12-13 BR BR112016013493-1A patent/BR112016013493B1/pt not_active IP Right Cessation
- 2014-12-13 KR KR1020167018560A patent/KR102454610B1/ko active Active
- 2014-12-13 MY MYPI2016702163A patent/MY175708A/en unknown
-
2015
- 2015-05-21 ZA ZA2015/03583A patent/ZA201503583B/en unknown
- 2015-06-12 MX MX2022016002A patent/MX2022016002A/es unknown
-
2016
- 2016-06-13 MX MX2021015971A patent/MX2021015971A/es unknown
- 2016-11-18 AU AU2016259451A patent/AU2016259451A1/en not_active Abandoned
-
2018
- 2018-04-30 AU AU2018202997A patent/AU2018202997A1/en not_active Abandoned
- 2018-06-12 US US16/005,997 patent/US20180346554A1/en not_active Abandoned
- 2018-09-26 US US16/142,457 patent/US11208470B2/en active Active
-
2019
- 2019-03-27 JP JP2019061531A patent/JP2019115355A/ja active Pending
- 2019-04-04 AU AU2019202343A patent/AU2019202343B2/en active Active
-
2020
- 2020-03-02 JP JP2020035240A patent/JP2020108381A/ja active Pending
- 2020-03-13 AU AU2020201853A patent/AU2020201853B2/en active Active
-
2021
- 2021-02-04 JP JP2021016537A patent/JP2021087433A/ja not_active Withdrawn
- 2021-06-03 AU AU2021203643A patent/AU2021203643A1/en not_active Abandoned
- 2021-12-17 US US17/554,642 patent/US20220112273A1/en not_active Abandoned
-
2023
- 2023-03-15 JP JP2023040876A patent/JP2023080085A/ja active Pending
- 2023-06-30 JP JP2023108341A patent/JP2023138998A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021087433A5 (enExample) | ||
| JP2016501535A5 (enExample) | ||
| US12116386B2 (en) | Chimeric molecules and uses thereof | |
| JP2017537621A5 (enExample) | ||
| CN107406518B (zh) | 嵌合抗原受体 | |
| Plückthun et al. | New protein engineering approaches to multivalent and bispecific antibody fragments | |
| JP4011914B2 (ja) | キメラポリペプチド、その製造方法、およびその使用 | |
| US20040220388A1 (en) | Novel heterodimeric fusion proteins | |
| JP2020515272A5 (enExample) | ||
| JPH08504320A (ja) | 標的結合性ポリペプチド | |
| JP2023058590A5 (enExample) | ||
| JP2018537415A (ja) | 多価Ｆｖ抗体 | |
| TW200808824A (en) | Binding molecules 3 | |
| WO2002033072A1 (fr) | Anticorps degrade, agoniste de tpo | |
| JP2019515666A5 (enExample) | ||
| JPWO2019195486A5 (enExample) | ||
| US20220218752A1 (en) | Lockr-mediated recruitment of car t cells | |
| CN117886928A (zh) | 与经工程改造的Fc构建体相关的组合物和方法 | |
| WO2004020639A2 (en) | Production of multimeric fusion proteins using a c4bp scaffold | |
| CN113439089A (zh) | 截短的多价多元体 | |
| JPWO2020065349A5 (enExample) | ||
| CN115397833A (zh) | 多聚体IgA抗体的制造方法与多特异性多聚体IgA抗体 | |
| Honjo | New flavivirus antigens for production of vaccines against Japanese encep/ml~ pimmid vector mmtrucflon and gem in Esdm, iehia coil Res. Found. Microbial Dis. Osaka Univ. Belgium; 16 March 1987 | |
| KR20250103763A (ko) | 융합 단백질 및 이를 포함하는 입자형 항원 | |
| HK40073047A (en) | A recombinant protein-based covid-19 vaccine as well as its preparation method and application thereof |